TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41921

Peptide_Name

Sample Peptide 1 from EP3604345B1

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 33-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR-NH2

FASTA

>TPDB41921|Anticancer|length=33
MQIPQAPWPVVWAVLQLGWRKKRTLRKNDRKKR-NH2

Formula C187H308N60O41S1

Absent Amino Acids CEHFSY

Common Amino Acids RK

Mass 4084.94

PI 12.59

Basic Residues 10

Acidic Residues 1

Hydrophobic Residues 13

Net Charge +9

Boman Index 5.99

Hydrophobicity -1.033

Aliphatic Index 79.70

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 16500

Absorbance 280nm 403.92

Polar Residues 5

number

2

A

5

R

1

N

1

D

0

C

0

E

3

Q

1

G

0

H

1

I

3

L

5

K

1

M

0

F

3

P

0

S

1

T

3

W

0

Y

3

V

Amino Acid Distribution

A: 2 R: 5 N: 1 D: 1 C: 0 E: 0 Q: 3 G: 1 H: 0 I: 1 L: 3 K: 5 M: 1 F: 0 P: 3 S: 0 T: 1 W: 3 Y: 0 V: 3

Length

33

Formula

C187H308N60O41S1

Mass

4084.94

PI

12.59

Net Charge

+9

Boman Index

5.99

Hydrophobicity

-1.033

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 6.8% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line NCI-H2444

Tissue Affected Lung

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1 US11352408B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 11.8% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line HCC-827

Tissue Affected Lung

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1

Evidence 3 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 0.5% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line NCI-H446

Tissue Affected Lung

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1

Evidence 4 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 6.7% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Skin Cancer

Cell Line A-2058

Tissue Affected Skin

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1

Evidence 5 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 62.3% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1